The overall response rate of the clinical trials for Abcema is 94%, with a CR rate of 40%, a duration of response of 10.6 months, and a progression-free survival of 8.6 months. Several adverse effects may also occur. Treatment with Abecma is available via a restricted program under the Abecma REMS. Source: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/4697-abcema-idecabtagene-vicleucel